Sequencing Within Reach
An Orthogonal Approach to Genome Sequencing
Downstream Processing Builds Pure Intensity
Bioprocessing Favors Go with the Flow over Stop and Go
Microfluidic Flows Enter Medical Mainstream
Microfluidic Readouts Could Flag Problems and Open the Door for New Treatment and Potential Early Intervention
Tumor Biomarkers Culled from Errant Transcripts
Potential for Blood Platelet–Derived Biomarkers to ID and Locate Tumors
For full access to this article login to GEN Select now.
Ready, Aim, CRISPR (or RNAi)
When targeting genes, drug developers may opt for knockdown via CRISPR or silencing via RNAi. These weapons, however, may fit different battle plans.
- Recent progress in probing gene function via the RNAi and CRISPR methods were a strong theme of the Discovery On Target conference, which took place last month in Boston. Both methods enable researchers to impair the function of a targeted gene. With RNAi (short for RNA interference), molecules ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.